Clinical Trials Regulations for Drugs

Summary#

This is a proposed new set of rules called the Clinical Trials Regulations under the Food and Drugs Act. It would give Health Canada direct, flexible oversight of clinical trials of drugs (replacing the current rules in Part C, Division 5 of the Food and Drug Regulations and the COVID-19 CT Regulations). The proposal is at the consultation stage (comments accepted for 90 days from publication) and would come into force 12 months after final publication in the Canada Gazette, Part II.

What it does#

• Creates a single, stand‑alone federal framework to regulate the conduct of drug clinical trials as well as the import and sale of trial drugs.
• Requires sponsors to hold an authorization for most trials, except some trials that use only already‑authorized drugs used exactly as approved.
• Lets the Minister impose targeted, case‑by‑case “terms and conditions” on authorizations to manage risk. These can be added or changed during a trial.
• Allows partial actions: the regulator could suspend or revoke just part of a trial (for example, one arm), not only whole trials.
• Brings third‑party service providers (for example, contract research organizations) under direct regulatory obligations and requires sponsors to give service‑provider contact details.
• Broadens who can be an investigator beyond physicians and dentists (for example, nurse practitioners), to support decentralized or remote trial models.
• Replaces “written informed consent” with “documented informed consent,” allowing electronic signatures or recorded/oral consent where allowed by law.
• Enables the use of a national research ethics board (a single REB that can approve a trial across multiple Canadian sites).
• Eases some burdens for trials involving authorized drugs (for example, optional labelling relief and selective record‑keeping of non‑serious adverse events where justified).
• Introduces new safety reporting and notification duties (including discretionary requests for case reports and up to 15 years of post‑trial reporting in rare long‑risk cases).
• Sets timelines for authorization processing: a contingent authorization would be issued within 7 days of a complete application and would normally convert to an authorization after 30 days (extendable to 60 days for complex trials).

Who's affected#

• Sponsors: drug companies, biotech firms, research hospitals and universities that run or pay for trials. The RIAS estimates industry savings of $23.3 million (PV) from labelling and record changes, but new industry costs of $7.3 million (PV) for added reporting and terms/conditions (net industry savings of $16 million (PV)).
• Service providers and contract research organizations. They would have direct legal duties and reporting obligations.
• Investigators and clinical teams, including a wider range of regulated health professionals who could lead sites.
• Research ethics boards (REBs) and any new national REBs that may be created.
• Health Canada, which would need additional resources (estimated cost $15.7 million (PV) over 10 years) to review and manage new duties.
• People who might join trials: patients, including those in rural or remote areas and people with rare diseases. The proposal aims to make participation easier through decentralized trial options.
• Small businesses: Health Canada estimates about 4 small businesses would be affected; net impacts for those small firms are quantified in the RIAS.
• Broader economy: Health Canada forecasts up to $3.3 billion (PV) in new R&D investment if the changes attract about 5 additional trials per year.

Why it matters#

• For patients: the rules aim to make Canada a more flexible and attractive place to run trials. That could mean more trials in Canada and earlier access to experimental treatments, especially for people who live far from major hospitals.
• For trial design: sponsors could use more complex and decentralized trial models (remote visits, electronic consent, broader investigators) that can speed recruitment and include more diverse participants.
• For safety oversight: Health Canada would get clearer powers to manage risk during a trial (for example by adding terms and conditions or suspending just the risky part of a trial), and could require longer‑term reporting in limited cases.
• For industry: some regulatory costs drop (labelling and record keeping in some cases) but new reporting and notification duties add administrative work and expense.
• For research infrastructure: giving service providers and REBs clearer roles may reduce confusion and speed multi‑site trials, but it also shifts some legal responsibility onto those organizations.
• Important to know: this is a proposed regulation. It is not law yet. The government is seeking feedback (the notice allows 90 days for comments).